prospect
cohort
studi
laboratoryconfirm
hospit
andor
icu
adult
influenza
patient
influenza
season
five
studi
center
includ
northwestern
univers
chicago
il
mount
sinai
hospit
toronto
canada
north
york
gener
hospit
toronto
canada
royal
adelaid
hospit
adelaid
australia
westmead
hospit
westmead
australia
written
inform
consent
obtain
patient
hospit
patient
follow
condit
screen
influenzalik
ill
ili
suspect
respiratori
infect
pneumonia
respiratori
infect
acut
respiratori
failur
eg
chronic
obstruct
pulmonari
diseas
exacerb
asthma
exacerb
fever
patient
laboratoryconfirm
influenza
use
studi
center
inhous
rtqpcr
elig
studi
influenzaposit
patient
underw
daili
nasopharyng
np
sampl
start
enrol
baselin
day
enrol
day
discharg
death
hospit
patient
patient
icu
develop
ili
hospit
patient
met
criteria
entri
studi
screen
pcr
patient
posit
infect
consent
particip
studi
observ
day
discharg
icu
patient
still
hospit
everyotherday
sampl
continu
second
week
day
hospit
discharg
nasopharyng
swab
collect
ml
univers
transport
medium
utm
copan
divid
across
multipl
aliquot
aliquot
could
prepar
immedi
specimen
kept
refriger
hour
specimen
could
process
within
hour
frozen
accord
manufactur
instruct
collect
vial
contain
swab
transport
medium
vigor
agit
vortex
mixer
fluid
releas
grab
end
swabstick
squeez
tip
inner
wall
vial
tube
centrifug
rpm
minut
supernat
aliquot
store
sampl
sent
locat
subsequ
analys
perform
addit
baselin
sampl
also
analyz
filmarray
respiratori
panel
biofir
diagnost
accord
manufactur
protocol
respiratori
panel
ivd
version
northern
hemispher
version
southern
hemispher
pouch
use
nucleic
acid
extract
np
sampl
use
easymag
extract
platform
intern
extract
control
iec
ad
sampl
rna
extract
describ
previous
rna
elut
store
realtim
pcr
perform
accord
center
diseas
control
prevent
cdc
protocol
influenza
viru
target
matrix
gene
panel
oligonucleotid
primer
dualli
label
hydrolysi
taqman
probe
previous
describ
amplif
detect
perform
lightcycl
instrument
roch
appli
scienc
sampl
test
duplic
quantif
cycl
valu
correct
loss
rna
extract
use
iec
standard
rna
dilut
seri
extern
quantif
control
eqc
test
duplic
rtqpcr
experi
vl
calcul
copiesml
use
eqc
standard
curv
linear
rang
copiesml
lower
limit
quantif
lloq
upper
limit
quantif
sampl
influenza
vl
lloq
detect
amount
influenza
rna
extrapol
lowest
extrapol
quantiti
could
measur
copiesml
quantif
influenza
b
virus
primer
target
gene
describ
cdc
use
infbfw
infbrv
infbprob
biosearch
technolog
rna
extract
pcr
condit
ident
influenza
rtqpcr
protocol
eqc
synthes
use
sequenc
influenza
strain
measur
infect
influenza
virus
tissu
cultur
infecti
dose
assay
madindarbi
canin
kidney
mdck
epitheli
cell
obtain
atcc
perform
growth
medium
includ
ml
ultramdck
serumfre
medium
vwr
ml
lglutamin
mm
life
technolog
gentamicin
mgml
life
technolog
infect
medium
consist
growth
medium
supplement
trypsin
life
technolog
ml
fungizon
amphotericin
b
life
technolog
sampl
test
replic
dilut
plate
mdck
cell
harvest
count
vicel
beckman
coulter
accord
manufactur
protocol
mdck
cell
seed
day
concentr
growth
medium
per
well
plate
column
plate
incub
overnight
day
serial
dilut
virus
column
subsequ
dilut
column
made
infect
medium
growth
medium
remov
mdck
cell
viru
dilut
ad
mdck
cell
column
infect
medium
ad
column
neg
control
column
influenza
strain
cultur
mdck
cell
use
posit
control
everi
experi
replic
empti
well
row
h
control
plate
fill
dilut
seri
column
subsequ
dilut
column
utm
neg
control
plate
incub
day
subsequ
cytopathogen
effect
score
visual
interpret
northern
hemispher
sampl
chemiluminesc
readout
atplit
kit
perkinelm
use
viewlux
equip
perkinelm
use
southern
hemispher
sampl
kit
highsensit
atpmonitor
onestep
addit
assay
kit
quantif
viabl
cell
well
score
posit
neg
infect
accord
cutoff
rel
luminesc
unit
defin
receiv
oper
characterist
analysi
posit
control
plate
valu
calcul
templat
base
upon
reedmuench
method
determin
amount
infecti
influenza
viru
hospit
valu
measur
baselin
followup
np
sampl
sixtyf
influenza
b
sampl
subject
base
filmarray
rtqpcr
data
exclud
analysi
although
antifung
fungizon
alreadi
ad
infect
medium
end
concentr
sampl
subject
still
fungi
contamin
therefor
invalid
linear
trend
vl
calcul
way
mixedeffect
tobit
regress
analysi
adapt
thiebaut
jacqmingadda
use
sasstat
softwar
nlmix
procedur
version
appli
tobit
regress
enabl
account
leftcensor
vl
valu
respect
limit
detect
lod
mixedeffect
analysi
allow
patient
randomli
affect
trend
slope
intercept
pearson
productmo
correl
coeffici
sampl
mean
estim
use
leftcensor
bivari
normal
likelihoodbas
approach
propos
lyle
et
al
figur
gener
use
r
version
confid
band
linear
trend
calcul
sampl
bivari
normal
distribut
base
regress
coeffici
intercept
slope
well
covari
matrix
n
studi
involv
studi
center
northern
hemispher
canada
unit
state
center
southern
hemispher
australia
total
patient
laboratoryconfirm
influenza
per
studi
center
inhous
rtqpcr
includ
tabl
followup
sampl
collect
influenza
rna
copi
number
valu
determin
coinfect
influenza
anoth
respiratori
viru
parainfluenza
type
coronaviru
bocaviru
rhinovirusenteroviru
detect
sampl
influenza
aposit
sampl
includ
analys
subset
sampl
pair
influenza
vl
data
avail
analyz
figur
avoid
upward
bia
caus
exclud
data
lod
ie
leftcensor
data
statist
calcul
use
maximum
likelihood
estim
procedur
lead
mean
influenza
vl
copiesml
confid
interv
ci
baselin
sampl
n
leftcensor
copiesml
ci
sampl
n
leftcensor
highest
observ
vl
copiesml
averag
error
number
day
vl
reach
detect
limit
day
sinc
enrol
sampl
leftcensor
detect
limit
rang
figur
mean
baselin
sampl
ci
n
leftcensor
sampl
ci
averag
error
number
day
reach
detect
limit
day
sinc
enrol
correl
vl
estim
ci
although
sampl
infecti
viral
particl
viral
rna
detect
variabl
level
viral
rna
absenc
cultiv
viru
obtain
sampl
figur
studi
vl
decreas
significantli
rate
copi
per
ml
per
day
p
figur
word
patient
influenza
vl
averag
underw
drop
everi
day
estim
decay
rate
per
ml
per
day
p
correspond
drop
everi
day
figur
rel
infect
defin
log
ratio
within
patient
chang
significantli
unit
per
day
p
figur
ratio
neg
mean
averag
patient
decay
faster
vl
observ
period
decay
correspond
declin
rel
infect
viral
rna
copi
thu
data
document
signific
declin
rel
infect
influenza
viru
particl
import
note
result
observ
irrespect
investig
site
subtyp
presenc
coinfect
one
largest
multicent
studi
defin
epidemiolog
influenza
hospit
patient
studi
enrol
influenzainfect
hospit
patient
influenza
season
serial
assess
viral
shed
studi
molecular
cell
cultur
method
method
highli
colinear
although
rate
decay
cell
culturebas
infecti
viral
titer
faster
observ
molecular
method
studi
document
clear
decreas
ratio
influenza
rna
copi
number
infecti
viral
titer
patient
time
clinic
diagnosi
limit
ili
symptom
specif
influenza
viru
infect
caus
respiratori
pathogen
influenza
vl
decay
quantifi
infecti
noninfecti
viral
particl
time
decay
quantifi
infecti
viral
particl
time
could
use
virolog
secondari
measur
studi
pair
influenza
vl
decay
decay
data
point
avail
sampl
vl
decay
copi
per
ml
per
day
studi
pronounc
compar
respiratori
tract
decreas
rate
vl
unit
per
day
report
lu
et
al
likewis
decay
compar
median
decay
rate
correspond
drop
everi
day
period
day
report
de
jong
et
al
mechan
prolong
viral
shed
ie
detect
influenza
viral
rna
longer
time
period
describ
mani
studi
clinic
infect
control
relev
detect
low
level
viral
rna
absenc
cultiv
viru
question
context
note
viru
cultur
method
less
sensit
molecular
method
improp
sampl
handl
could
also
impact
studi
high
percentag
sampl
n
level
viral
rna
absenc
cultiv
viru
np
swab
despit
proper
sampl
handl
import
includ
percentag
infecti
viral
particl
virolog
measur
use
clinic
studi
antivir
agent
unlik
assess
vl
human
immunodefici
viru
hepat
plasma
use
input
sampl
assess
influenza
vl
util
respiratori
specimen
variabl
titer
viru
upper
lower
airway
addit
signific
variabl
due
sampl
method
keep
variabl
relat
sampl
collect
process
transport
low
possibl
well
defin
collect
ship
instruct
provid
clinic
site
shown
signific
declin
log
ratio
time
within
patient
absolut
chang
vl
due
variat
sampl
method
could
captur
use
ratio
virolog
measur
instead
use
influenza
vl
conclus
epidemiolog
studi
contribut
understand
viral
shed
pattern
influenzainfect
hospit
adult
patient
viral
rna
copi
number
viral
infecti
titer
pattern
patient
demonstr
downward
trend
log
ratio
influenza
virus
ratio
less
affect
sampl
variabl
valu
could
use
determin
efficaci
new
antivir
compound
futur
studi
could
includ
ratio
virolog
measur
investig
clinic
relev
